Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
73Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $311.71M | $163.06M | $2.25 |
| 2024 | $43.47M | $-17.93M | $-0.30 |
| 2023 | $0.00 | $-46.34M | $-0.91 |
| 2022 | $65.4K | $-29.70M | $-0.74 |
| 2021 | $190.9K | $-28.21M | $-0.75 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.10 per share
Typical surprise +21.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$0.29 vs $0.24beat
- Thu, May 14$0.43 vs $0.35beat
- Thu, Mar 5$0.61 vs $0.86miss
- Wed, Nov 12$0.57 vs $0.48beat
- Thu, Aug 7$0.28 vs $0.20beat
- Tue, May 6$0.30 vs $0.25beat
Estimates and results for CRMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.33
- Implied price
- $16.63
- Return from $7.54
- 17.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $8.27 — today's price is already 8.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 1 | 3 | 5 | 7 | 9 |
|---|---|---|---|---|---|
| -2.0% | -23.0% | -4.0% | 6.3% | 13.7% | 19.6% |
| 3.0% | -19.0% | 0.9% | 11.7% | 19.5% | 25.7% |
| 8.0% | -15.1% | 5.8% | 17.1% | 25.3% | 31.8% |
| 13.0% | -11.2% | 10.7% | 22.6% | 31.1% | 37.9% |
| 18.0% | -7.2% | 15.6% | 28.0% | 36.9% | 44.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (5)
- Newszacks.com·1d ago·Positive
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.
View source ↗ - Newsseekingalpha.com·2d ago·Positive
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·2d ago·Positive
CorMedix Q2 Earnings Call Highlights CorMedix NASDAQ: CRMD reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted EBITDA guidance. The company also said it signed a multiyear commercial supply agreement for DefenCath with an additional large dialysis organization, giving it supply agreements with each of the five largest U.S. dialysis providers.
View source ↗ - Newszacks.com·2d ago·Positive
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates CorMedix (CRMD) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.28 per share a year ago.
View source ↗ - Newsglobenewswire.com·2d ago·Neutral
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.
View source ↗